Peter Ravdin

Peter Ravdin

UNVERIFIED PROFILE

Are you Peter Ravdin?   Register this Author

Register author
Peter Ravdin

Peter Ravdin

Publications by authors named "Peter Ravdin"

Are you Peter Ravdin?   Register this Author

54Publications

1389Reads

50Profile Views

Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer.

N Engl J Med 2019 06 3;380(25):2395-2405. Epub 2019 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); University of Texas, San Antonio (P.M.R.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O., J.A.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); the National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and the University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and the University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1904819DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709671PMC
June 2019

Communicating Risks of Adjuvant Chemotherapy for Breast Cancer: Getting Beyond the Laundry List.

J Oncol Pract 2019 Feb 14;15(2):e98-e109. Epub 2018 Dec 14.

5 UCLA School of Medicine, Los Angeles, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JOP.18.00162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374637PMC
February 2019

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2018 Jul 3;379(2):111-121. Epub 2018 Jun 3.

From Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.), and McMaster University, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Chicago Stritch School of Medicine, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), and Duke University Medical Center, Durham (J.A.O.) - both in North Carolina; Mayo Clinic, Jacksonville, FL (M.P.G.); National Institutes of Health, National Cancer Institute, Bethesda, MD (T.L., J.A.); Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.), Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Washington University, St. Louis (M.J.E.); National Surgical Adjuvant Breast and Bowel Project Pathology Office (S.P.) and University of Pittsburgh (A.M.B.), Pittsburgh; Emory University, Atlanta (W.C.W.); University of Texas, San Antonio (P.M.R.); Cancer Trials Ireland, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); and University of Hawaii Cancer Center, Honolulu (J.L.B.).

View Article

Download full-text PDF

Source
http://www.nejm.org/doi/10.1056/NEJMoa1804710
Publisher Site
http://dx.doi.org/10.1056/NEJMoa1804710DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6172658PMC
July 2018

Accuracy of the online prognostication tools PREDICT and Adjuvant! for early-stage breast cancer patients younger than 50 years.

Eur J Cancer 2017 06 14;78:37-44. Epub 2017 Apr 14.

Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Division of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2017.03.015DOI Listing
June 2017

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer.

N Engl J Med 2016 Aug;375(8):717-29

From Champalimaud Clinical Center-Champalimaud Foundation, Lisbon, Portugal (F.C.); Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco (L.J.V.); European Organization for Research and Treatment of Cancer Headquarters (J.B., L. Slaets, V.G., B.M., K.T.), Breast International Group Headquarters (T.G., C. Straehle), and Institut Jules Bordet, Université Libre de Bruxelles (C. Sotiriou, M.P.), Brussels, and Centre Hospitalier Universitaire Université Catholique de Louvain, Namur (P.V.) - both in Belgium; University of Milan and Istituto Europeo di Oncologia (G.V.) and Europa Donna-European Breast Cancer Coalition (S.K.), Milan, and Azienda Istituti Ospitalieri di Cremona, Cremona (R.P.) - both in Italy; Gustave Roussy, Villejuif (S.D., M.S.), Institut Curie Paris Sciences et Lettres, Université Paris Descartes, Sorbonne Paris Cité, Paris (J.-Y.P.). Institut Curie-Hôpital Rene Huguenin, Saint-Cloud (E.B.), and Centre Georges-Francois-Leclerc, Dijon (S.C.) - all in France; Swiss Institute of Bioinformatics and University of Lausanne, Lausanne, Switzerland (M.D.); Agendia (A.M.G., L. Stork) and the Netherlands Cancer Institute (R.B., E.R.), Amsterdam, Alrijne Ziekenhuis, Rijnland Leiderdorp (P.A.N.), Jeroen Bosch Hospital, 's-Hertogenbosch (T.J.S.), and Medisch Centrum Alkmaar, Alkmaar (J.M.H.) - all in the Netherlands; Institute of Oncology, Ljubljana, Slovenia (E.M.); Evangelisches Krankenhaus Bethesda, Duisburg, Germany (U.N.); University of Texas Health Sciences Center, San Antonio (P.R.); Hospital Universitario Vall d'Hebron, Barcelona (I.T.R.); Imperial College London, London (G.T.); and University of Texas M.D. Anderson Cancer Center, Houston (A.M.T.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1602253DOI Listing
August 2016

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer.

N Engl J Med 2015 Nov 27;373(21):2005-14. Epub 2015 Sep 27.

From the Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY (J.A.S., D.F.M.); Dana-Farber Cancer Institute, Boston (R.J.G.); Sunnybrook Research Institute, Toronto (K.I.P.) and Juravinski Cancer Center, Hamilton, ON (T.J.W.) - both in Canada; Loyola University Medical Center, Maywood (K.S.A.), and Northwestern University, Chicago (L.I.W., V.G.K.) - both in Illinois; University of Michigan, Ann Arbor (D.F.H.); Virginia Commonwealth University School of Medicine and the Massey Cancer Center, Richmond (C.E.G.); University of North Carolina, Chapel Hill (E.C.D.), Duke University Medical Center, Durham (J.A.O.), Wake Forest University Health Service, Winston-Salem (L.I.W.), and Southeast Clinical Oncology Research Consortium, Goldsboro (J.N.A.) - all in North Carolina; Mayo Clinic, Jacksonville, FL (E.A.P.); University of Maryland School of Medicine, Baltimore (J.A.O.), and National Institutes of Health, Bethesda (J.Z., T.L.) - both in Maryland; Indiana University School of Medicine (S.S.B.) and Indiana University Hospital (G.W.S.) - both in Indianapolis; Vince Lombardi Cancer Clinic, Two Rivers (T.J.S.), and Fox Valley Hematology and Oncology, Appleton (T.F.G.) - both in Wisconsin; Baylor College of Medicine, Houston (M.J.E.), and University of Texas, San Antonio (P.R.) - both in Texas; Washington University, St. Louis (M.J.E.); Allegheny General Hospital (S.P.) and University of Pittsburgh (A.M.B.) - both in Pittsburgh; the Department of Medical Oncology and Breast Center, Yonsei University College of Medicine, Seoul, South Korea (S.P.); Emory University, Atlanta (W.C.W.); Irish Clinical Oncology Research Group, Dublin (M.M.K.); Instituto Nacional de Enfermedades Neoplásicas, Lima, Peru (H.L.G.M.); Cancer Center of Kansas, Wichita (P.S.R.); Vanderbilt University, Nashville (I.A.M.); Rutgers Cancer Institute of New Jersey, New Brunswick (D.L.T.); University of Hawaii Cancer Center, Honolulu (J.L.B.); and Stanford University, Stanford, CA (G.W.S.)

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1510764DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4701034PMC
November 2015

Epidemiology of GIST in the Era of Histology Codes--Letter.

Cancer Epidemiol Biomarkers Prev 2015 Jun;24(6):998

The University of Texas Health Sciences Center, San Antonio, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1055-9965.EPI-15-0001DOI Listing
June 2015

Genome-wide DNA methylation profiling reveals parity-associated hypermethylation of FOXA1.

Breast Cancer Res Treat 2014 Oct 19;147(3):653-9. Epub 2014 Sep 19.

Department of Molecular Medicine, Cancer Therapy and Research Center, University of Texas Health Science Center at San Antonio, San Antonio, TX, 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10549-014-3132-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4181377PMC
October 2014

Hormone replacement therapy and the increase in the incidence of invasive lobular cancer.

Authors:
Peter M Ravdin

Breast Dis 2008-2009;30:3-8

University of Texas Health Sciences Center, San Antonio, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3233/BD-2009-0283DOI Listing
December 2012

Independent prognostic value of screen detection in invasive breast cancer.

J Natl Cancer Inst 2011 Apr 24;103(7):585-97. Epub 2011 Feb 24.

Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djr043DOI Listing
April 2011

The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention.

Authors:
Peter M Ravdin

Cancer Prev Res (Phila) 2010 Jun;3(6):686-8

University of Texas Health Sciences Center at San Antonio, 78229, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1940-6207.CAPR-10-0100DOI Listing
June 2010

Ki67 in breast cancer: prognostic and predictive potential.

Lancet Oncol 2010 Feb;11(2):174-83

Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(09)70262-1DOI Listing
February 2010

Sustained lower rates of breast cancer in the United States.

Breast Cancer Res Treat 2009 Sep 1;117(1):223-4. Epub 2008 Nov 1.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s10549-008-0226-8
Publisher Site
http://dx.doi.org/10.1007/s10549-008-0226-8DOI Listing
September 2009

Patterns of treatment for early stage breast cancers at the M. D. Anderson Cancer Center from 1997 to 2004.

Cancer 2009 May;115(10):2041-51

Department of Biostatistics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.24271DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2716402PMC
May 2009

The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

Oncologist 2009 Apr 3;14(4):320-68. Epub 2009 Apr 3.

Department of Pathology and Laboratory Medicine, Albany Medical College, Albany, NY 12208, USA.

View Article

Download full-text PDF

Source
http://theoncologist.alphamedpress.org/cgi/doi/10.1634/theon
Publisher Site
http://dx.doi.org/10.1634/theoncologist.2008-0230DOI Listing
April 2009

Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer.

J Clin Oncol 2008 May 31;26(13):2112-7. Epub 2008 Mar 31.

Department of Radiation Medicine, KPV4, Oregon Health and Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239-3098, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2007.14.7934DOI Listing
May 2008

Overview of randomized trials of systemic adjuvant therapy.

Authors:
Peter Ravdin

Cancer Treat Res 2008 ;141:55-62

Division of Oncology, Health Science Center, University of Texas-San Antonio 78284, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-0-387-73161-2_4DOI Listing
March 2008

Building a predictive breast cancer risk model.

AMIA Annu Symp Proc 2007 Oct 11:995. Epub 2007 Oct 11.

The University of Texas M. D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
October 2007

Breast cancer trends: a marriage between clinical trial evidence and epidemiology.

J Natl Cancer Inst 2007 Aug 24;99(15):1139-41. Epub 2007 Jul 24.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djm080DOI Listing
August 2007

The decrease in breast-cancer incidence in 2003 in the United States.

N Engl J Med 2007 Apr;356(16):1670-4

Department of Biostatistics, M.D. Anderson Cancer Center, Houston, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMsr070105DOI Listing
April 2007

A decision aid to assist in adjuvant therapy choices for breast cancer.

Psychooncology 2006 Nov;15(11):1001-13

Case Western Reserve University, Cleveland, OH 44106-4976, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pon.1040DOI Listing
November 2006

Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial.

Nat Clin Pract Oncol 2006 Oct;3(10):540-51

Medical Oncology & Translational Research, Jules Bordet Institute, Boulevard de Waterloo 125, 1000 Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncponc0591DOI Listing
October 2006

Defining the role of aromatase inhibitors in the adjuvant endocrine treatment of early breast cancer.

Curr Med Res Opin 2006 Aug;22(8):1575-85

University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1185/030079906X120940DOI Listing
August 2006

Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables.

Lung Cancer 2006 May 29;52(2):207-12. Epub 2006 Mar 29.

Division of Medical Oncology, University of Texas Health Sciences Center at San Antonio, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lungcan.2006.01.016DOI Listing
May 2006

Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information.

Med Decis Making 2005 May-Jun;25(3):301-7

Department of Health Policy & Management, Graduate School of Public Health, University of Pittsburgh, PA 15261, USA.

View Article

Download full-text PDF

Source
http://mdm.sagepub.com/content/25/3/301.full.pdf
Web Search
http://mdm.sagepub.com/cgi/doi/10.1177/0272989X05276851
Publisher Site
http://dx.doi.org/10.1177/0272989X05276851DOI Listing
November 2005

Population-based validation of the prognostic model ADJUVANT! for early breast cancer.

J Clin Oncol 2005 Apr;23(12):2716-25

Breast Cancer Outcomes Unit, Vancouver Island Centre, 2410 Lee Avenue, Victoria, BC V8R 6V5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2005.06.178DOI Listing
April 2005

A method for making estimates of the benefit of the late use of letrozole in patients completing 5 years of tamoxifen.

Clin Breast Cancer 2004 Oct;5(4):313-6

Division of Oncology, University of Texas Health Sciences Center, San Antonio, USA.

View Article

Download full-text PDF

Source
October 2004

Managing the risk of osteoporosis in women with a history of early breast cancer.

Authors:
Peter M Ravdin

Oncology (Williston Park) 2004 Oct;18(11):1385-90, 1393; discussion 1394

University of Texas Health Science Center San Antonio, Texas 78259-2307, USA.

View Article

Download full-text PDF

Source
October 2004

A Southwest Oncology Group Randomized Phase II Study of doxorubicin and paclitaxel as frontline chemotherapy for women with metastatic breast cancer.

Breast Cancer Res Treat 2004 05;85(2):143-50

James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine, Strong Memorial Hospital, Rochester, NY 14642-0001, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/B:BREA.0000025405.63953.f9DOI Listing
May 2004

Decision-making for patients with resectable breast cancer: individualized decisions for and by patients and their physicians.

J Natl Compr Canc Netw 2003 Apr;1(2):189-96

Mayo Clinic, Rochester, Minnesota 550905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2003.0017DOI Listing
April 2003

Choosing between endocrine therapy and chemotherapy--or is there a role for combination therapy?

Breast Cancer Res Treat 2002 Oct;75 Suppl 1:S37-44; discussion S57-9

Department of Surgical Oncology, University of Newcastle, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1023/a:1020365800921DOI Listing
October 2002

Aromatase inhibitors for the endocrine adjuvant treatment of breast cancer.

Authors:
Peter Ravdin

Lancet 2002 Jun;359(9324):2126-7

Department of Medical Oncology, University of Texas Health Science Center, San Antonio, TX 98284-7884, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0140-6736(02)09111-0DOI Listing
June 2002

Doctor-patient communication patterns in breast cancer adjuvant therapy discussions.

Health Expect 2000 Mar;3(1):26-36

Case Western Reserve University, Cleveland, Ohio, USA; University of Texas, San Antonio, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5081082PMC
http://dx.doi.org/10.1046/j.1369-6513.2000.00074.xDOI Listing
March 2000